Cite

    Luo, H. et al. (2021). Safety risk management for low molecular weight process‐related impurities in monoclonal antibody therapeutics: Categorization, risk assessment, testing strategy, and process development with leveraging clearance potential. Biotechnology progress. p. n/a. [Online].